EICHORCondition: Thyroid Eye Disease, TED · Graves Orbitopathy · Sponsor: Sling Therapeutics, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
This description comes directly from the study's public registry record.
Cathy Radovich · (734) 223-1786 · cathy.radovich@slingtx.com
Always discuss trial participation with your own doctor first.
| Advancing Research International | Las Vegas, Nevada, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07753603